Astrocytoma
89
14
22
40
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
16 trials with published results (18%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.6%
13 terminated out of 89 trials
75.5%
-11.1% vs benchmark
6%
5 trials in Phase 3/4
40%
16 of 40 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 40 completed trials
Clinical Trials (89)
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Pediatric Long-Term Follow-up and Rollover Study
GliomaAI-Astro4: MRI-Based Detection of IDH Mutant Astrocytoma Grade 4
GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3)
Social Determinants of Health in Glioblastoma Population
Astrocytoma / Desmoplastic Gamliogliomes (DIA / DIG) - Study of the French Cohort of the Last 20 Years : Clinical, Anatomopathological, Molecular and Radiological Charactersics
Study of Olutasidenib and Temozolomide in HGG
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
Investigational Imaging Technique During Brain Surgery
Tuvusertib in Astrocytoma With ATRX Mutation
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Venous Thromboembolism Prevention in Outpatients With Glioma